GRAIL

GRAIL, Inc. is a spin-off from DNA sequencing giant Illumina, established in 2015. It is an early cancer diagnostic company in the clinical stage with the mission to detect cancer early when it is still curable. GRAIL is dedicated to reducing the global cancer burden by developing groundbreaking technologies for the early detection and identification of multiple lethal cancer types. The company leverages next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance scientific understanding of cancer biology and develop its multi-cancer early detection blood test. Headquartered in California, the company also has facilities in Washington, D.C., and the UK.